Jama Oncology最新文献

筛选
英文 中文
Methodology Concerns Regarding Claims Data Studies in Transgender Health-Reply. 关于跨性别健康索赔数据研究的方法学问题-回复。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2025-05-01 DOI: 10.1001/jamaoncol.2025.0026
Celeste Manfredi, Marco De Sio, Riccardo Autorino
{"title":"Methodology Concerns Regarding Claims Data Studies in Transgender Health-Reply.","authors":"Celeste Manfredi, Marco De Sio, Riccardo Autorino","doi":"10.1001/jamaoncol.2025.0026","DOIUrl":"10.1001/jamaoncol.2025.0026","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"568-569"},"PeriodicalIF":28.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Accelerated Aging in Survivors of Childhood Cancer-Early Onset and Excess Risk of Chronic Conditions. 儿童癌症幸存者的加速衰老——早期发病和慢性疾病的过度风险。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2025-05-01 DOI: 10.1001/jamaoncol.2025.0236
Jennifer M Yeh, Zachary J Ward, Kayla L Stratton, Mercedes V McMahon, Chelsea S Taylor, Gregory T Armstrong, Eric J Chow, Melissa M Hudson, Lindsay M Morton, Kevin C Oeffinger, Lisa R Diller, Wendy M Leisenring
{"title":"Accelerated Aging in Survivors of Childhood Cancer-Early Onset and Excess Risk of Chronic Conditions.","authors":"Jennifer M Yeh, Zachary J Ward, Kayla L Stratton, Mercedes V McMahon, Chelsea S Taylor, Gregory T Armstrong, Eric J Chow, Melissa M Hudson, Lindsay M Morton, Kevin C Oeffinger, Lisa R Diller, Wendy M Leisenring","doi":"10.1001/jamaoncol.2025.0236","DOIUrl":"10.1001/jamaoncol.2025.0236","url":null,"abstract":"<p><strong>Importance: </strong>The lifetime risk of aging-related diseases among survivors of childhood cancer, accelerated by cancer treatment exposures, is unknown. Understanding this risk can provide a more comprehensive assessment of long-term health across the lifespan of survivors and guide adult care.</p><p><strong>Objective: </strong>To estimate the lifetime risks of 8 treatment-related cancers and cardiovascular conditions among childhood cancer survivors and compare them with the general population.</p><p><strong>Design, setting, participants: </strong>Using data from the Childhood Cancer Survivor Study and national databases, this simulation modeling study projected long-term outcomes for 5-year survivors diagnosed between 1970 and 1999 based on treatment exposures and age-related risks. The general population comparator was simulated using age-, sex-, and calendar year-matched individuals who faced only age-related risks.</p><p><strong>Exposures: </strong>Treatment era (1970s, 1980s, 1990s), original cancer diagnosis, radiation treatment for primary diagnosis (any, none).</p><p><strong>Main outcomes and measures: </strong>Estimated lifetime risks of 8 health conditions (breast cancer, colorectal cancer, glial tumors, sarcomas, heart failure, coronary heart disease/myocardial infarction, stroke, and valvular disease). Risks were projected and compared with the general population, stratified by radiation exposure.</p><p><strong>Results: </strong>In the general population, 20% developed at least 1 health condition by age 65.0 years; in 5-year survivors this threshold was reached at age 47.3 years, representing a 17.7-year (95% uncertainty interval [UI], 14.0-21.0) acceleration in disease onset. By age 65 years, 55% of survivors were projected to develop at least 1 condition, indicating a 2.7-fold (95% UI, 2.2-3.5) higher relative risk and 34.2% (95% UI, 28.3-42.5) absolute excess risk compared with the general population. Risks were higher among those treated with radiation therapy for childhood cancer (22.0 years earlier onset [95% UI, 18.0-25.0]; 37.3% excess risk [95% UI, 31.6%-44.7%]) but still elevated for those without radiation exposure (13.5 years earlier onset [95% UI, 10.0-16.0]; 31.0% excess risk [95% UI, 23.9%-40.3%]). Reaching middle age was still associated with increased health risks. Compared with the general population, survivors who reached age 40 years had a 6.2-fold higher risk (95% UI, 4.8-9.4) of developing a new condition within 10 years.</p><p><strong>Conclusions and relevance: </strong>This study found that survivors of childhood cancer experience accelerated onset of aging-related diseases, regardless of prior radiation exposure. These findings underscore the importance of prioritizing cancer and cardiovascular disease prevention among survivors decades earlier than for the general population.</p>","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"535-543"},"PeriodicalIF":28.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Veliparib Plus Temozolomide for MGMT-Methylated Glioblastoma-Reply. Veliparib +替莫唑胺治疗mgmt -甲基化胶质母细胞瘤
IF 28.4 1区 医学
Jama Oncology Pub Date : 2025-05-01 DOI: 10.1001/jamaoncol.2025.0032
Jann N Sarkaria, Sani H Kizilbash, Caterina Giannini
{"title":"Veliparib Plus Temozolomide for MGMT-Methylated Glioblastoma-Reply.","authors":"Jann N Sarkaria, Sani H Kizilbash, Caterina Giannini","doi":"10.1001/jamaoncol.2025.0032","DOIUrl":"10.1001/jamaoncol.2025.0032","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"569-570"},"PeriodicalIF":28.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identifying Who Is at Risk of Interval Breast Cancers. 确定谁有间隔期乳腺癌的风险。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2025-05-01 DOI: 10.1001/jamaoncol.2025.0101
Christoph I Lee, Kathryn P Lowry
{"title":"Identifying Who Is at Risk of Interval Breast Cancers.","authors":"Christoph I Lee, Kathryn P Lowry","doi":"10.1001/jamaoncol.2025.0101","DOIUrl":"10.1001/jamaoncol.2025.0101","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"527-528"},"PeriodicalIF":28.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143722084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Veliparib Plus Temozolomide for MGMT-Methylated Glioblastoma. Veliparib +替莫唑胺治疗mgmt甲基化胶质母细胞瘤。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2025-05-01 DOI: 10.1001/jamaoncol.2025.0029
Liam Wilson, Aline Atallah
{"title":"Veliparib Plus Temozolomide for MGMT-Methylated Glioblastoma.","authors":"Liam Wilson, Aline Atallah","doi":"10.1001/jamaoncol.2025.0029","DOIUrl":"10.1001/jamaoncol.2025.0029","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"569"},"PeriodicalIF":28.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
JAMA Oncology-The Year in Review, 2024. 美国医学会肿瘤学杂志:回顾一年,2024。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2025-05-01 DOI: 10.1001/jamaoncol.2025.0312
Mary L Nora Disis
{"title":"JAMA Oncology-The Year in Review, 2024.","authors":"Mary L Nora Disis","doi":"10.1001/jamaoncol.2025.0312","DOIUrl":"10.1001/jamaoncol.2025.0312","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"483-484"},"PeriodicalIF":28.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
JAMA Oncology Peer Reviewers in 2024. 2024年JAMA肿瘤学同行评审。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2025-05-01 Epub Date: 2025-05-15 DOI: 10.1001/jamaoncol.2025.0349
{"title":"JAMA Oncology Peer Reviewers in 2024.","authors":"","doi":"10.1001/jamaoncol.2025.0349","DOIUrl":"https://doi.org/10.1001/jamaoncol.2025.0349","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":"11 5","pages":"e250349"},"PeriodicalIF":28.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144081297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
On Accelerated Aging-A Phenomenon in Survivors of Childhood Cancer. 加速衰老——儿童癌症幸存者的一种现象
IF 28.4 1区 医学
Jama Oncology Pub Date : 2025-05-01 DOI: 10.1001/jamaoncol.2025.0130
Smita Bhatia, F Lennie Wong
{"title":"On Accelerated Aging-A Phenomenon in Survivors of Childhood Cancer.","authors":"Smita Bhatia, F Lennie Wong","doi":"10.1001/jamaoncol.2025.0130","DOIUrl":"10.1001/jamaoncol.2025.0130","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"485-486"},"PeriodicalIF":28.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143665201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers: A Review. 儿童肿瘤学组儿童、青少年和青年癌症幸存者长期随访指南》:回顾。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2025-05-01 DOI: 10.1001/jamaoncol.2024.6812
Anna DeVine, Wendy Landier, Melissa M Hudson, Louis S Constine, Smita Bhatia, Saro H Armenian, Maria M Gramatges, Eric J Chow, Danielle Novetsky Friedman, Matthew J Ehrhardt
{"title":"The Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers: A Review.","authors":"Anna DeVine, Wendy Landier, Melissa M Hudson, Louis S Constine, Smita Bhatia, Saro H Armenian, Maria M Gramatges, Eric J Chow, Danielle Novetsky Friedman, Matthew J Ehrhardt","doi":"10.1001/jamaoncol.2024.6812","DOIUrl":"10.1001/jamaoncol.2024.6812","url":null,"abstract":"<p><strong>Importance: </strong>Since 2003, the Children's Oncology Group (COG) has developed and disseminated the Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. These guidelines have benchmarked the standard of care for long-term survivors of childhood cancer in North America and beyond. Since their inception, they have evolved in depth, scope, and contributors to maintain fidelity toward continually emerging evidence related to cancer survivorship. They are intended to inform care for individuals who survived 2 or more years from completion of childhood, adolescent, and young adult cancer-directed therapy and receiving care in either specialty or primary care environments. The guidelines are updated on a 5-year cycle, during which comprehensive literature searches pertaining to guideline-specific questions are performed, evidence abstracted from pertinent publications, and recommendations determined and scored following expert deliberation.</p><p><strong>Observations: </strong>Version 6.0 of the guidelines, released in October 2023, comprised 165 sections and 45 health links and represents the cooperative efforts of 220 individuals. Major changes include the addition of recommendations regarding surveillance for genetic cancer predisposition, surveillance following the use of novel cancer treatment modalities, and routine vaccination practices during long-term follow-up. In addition, surveillance echocardiograms were omitted for those at low risk of cardiomyopathy.</p><p><strong>Conclusions and relevance: </strong>This narrative review outlines the historical evolution of the COG Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, current methods guiding their development, and key recommendations from version 6.0. The guidelines are publicly available in their entirety online. The COG guidelines continue to set the standard for surveillance practices for long-term survivors of childhood, adolescent, and young adult cancer. The growing body of evidence supporting these recommendations will continue to guide their evolution to inform optimal survivorship care practices.</p>","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"544-553"},"PeriodicalIF":28.4,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143460275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Errors in Visual Abstract. 视觉抽象中的错误。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2025-04-01 DOI: 10.1001/jamaoncol.2025.0254
{"title":"Errors in Visual Abstract.","authors":"","doi":"10.1001/jamaoncol.2025.0254","DOIUrl":"10.1001/jamaoncol.2025.0254","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"435"},"PeriodicalIF":28.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143460292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信